Richard L. Wahl

Mallinckrodt (United States) — United States

Medicine · Health Sciences

104h-index47.0kcitations912works6.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Medical Imaging Techniques and Applications(362), Radiomics and Machine Learning in Medical Imaging(243), Radiopharmaceutical Chemistry and Applications(192), Lymphoma Diagnosis and Treatment(95), Lung Cancer Treatments and Mutations(70)

Publications907 total

Safety and preliminary efficacy results of [ <sup>212</sup> Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs).
Journal of Clinical Oncology·2026
Abstract C095: [212Pb]VMT-a-NET for somatostatin receptor subtype 2 (SSTR2)-expressing tumors: safety and preliminary efficacy results in patients with advanced neuroendocrine tumors (NETs)
Molecular Cancer Therapeutics·2025
SRIP: A Self-Refined Iterative Pipeline to Integrate Whole Body MRI-CT Registration and Pseudo-CT Generation
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition·2025
1033MO [212Pb]VMT-α-NET targeted alpha-particle therapy (TAT) for advanced somatostatin receptor 2-positive (SSTR2+) neuroendocrine tumours (NETs): Mature safety and preliminary efficacy for enrollment from dose-finding cohorts 1 and 2 (n=44)
Annals of Oncology·2025
Interim safety and efficacy data of [ <sup>212</sup> Pb]VMT01 in MC1R expressing melanoma.
Journal of Clinical Oncology·2025· 1 cited
[ <sup>212</sup> Pb]VMT-α-NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and preliminary report for expansion participants.
Journal of Clinical Oncology·2025· 2 cited
Multiplex Spatial Proteomic Analysis of HER2–Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response
JCO Precision Oncology·2025· 1 cited
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
The Breast·2025· 2 citedOpen Access
Interim safety and efficacy data of [ <sup>212</sup> Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs).
Journal of Clinical Oncology·2025· 2 cited
Quantitative and Visual Benefits of Data-Driven Motion Correction on Oncologic PET/CT: A Prospective Cross-sectional Study
Academic Radiology·2025Open Access
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)
UNC Libraries·2025Open Access
Diagnosis of Stage IV Melanoma
2024
68Ga-DOTATATE and 18F-FDG PET/CT in a Rapidly Progressing Lymphoma
Clinical Nuclear Medicine·2024· 1 cited
Radiomic Texture Features in CT Images of Kidneys in Ventilated Deceased Donors Predict Delayed Graft Function
Journal of the American Society of Nephrology·2024
Radiotherapy and theranostics: a Lancet Oncology Commission
The Lancet Oncology·2024· 94 citedOpen Access
A low-count quantitative SPECT method for Actinium-225-based alpha-particle therapies
2024
Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence?
Journal of Nuclear Medicine·2024· 2 citedOpen Access
Joint Regional Uptake Quantification of Thorium-227 and Radium-223 Using a Multiple-Energy-Window Projection-Domain Quantitative SPECT Method
IEEE Transactions on Medical Imaging·2024· 9 citedOpen Access
The Rebirth of Radioimmunotherapy of Non-Hodgkin Lymphoma: The Phoenix of Nuclear Medicine?
Seminars in Nuclear Medicine·2024· 3 citedOpen Access
RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026).
Journal of Clinical Oncology·2024
page 1 of 46Next →

Frequent Co-authors

Kenneth Zasadny(10), Mark Kaminski(8), Christian Cohade(7), Medhat Osman(5), Martin A. Lodge(4), Susan J. Fisher(4), Mitsuaki Tatsumi(4), Isaac R. Francis(4), Yuji Nakamoto(4), Melissa Tuck(3), Judith Estes(3), Charles W. Ross(3), Denise Regan(3), Paul V. Kison(3), Stewart Kroll(3), Gary D. Hutchins(3), Andrew D. Zelenetz(3), Robert Stagg(3), George F. Tidmarsh(3), Susan J. Knox(3)